1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
Schindler, Suzanne E. ; Jicha, Gregory A. ; Nelson, Peter T. ; Keene, C. Dirk ; Blennow, Kaj LU ; Molinuevo, José Luis ; Masters, Colin L. ; Hansson, Oskar LU
; Teunissen, Charlotte E.
and Galasko, Douglas
, et al.
(2020)
In Journal of Alzheimer's disease : JAD
76(1).
p.27-31
Mark
- 2019
-
Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
Shaw, Leslie M. ; Hansson, Oskar LU
; Manuilova, Ekaterina
; Masters, Colin L.
; Doecke, James D.
; Li, Qiao Xin
; Rutz, Sandra
; Widmann, Monika
; Leinenbach, Andreas
and Blennow, Kaj
LU
(2019)
In Clinical Biochemistry
72.
p.7-14
Mark
-
Determining clinically meaningful decline in preclinical Alzheimer disease
Insel, Philip S. LU ; Weiner, Michael ; Mackin, R. Scott ; Mormino, Elizabeth ; Lim, Yen Ying ; Stomrud, Erik LU ; Palmqvist, Sebastian LU
; Masters, Colin L.
; Maruff, Paul T.
and Hansson, Oskar
LU
, et al.
(2019)
In Neurology
93(4).
p.322-333
Mark
- 2005
- The amyloid precursor protein(APP)of Alzheimer's disease and its paralog APLP2 modulate the Cu/Zn-NO-catalyzed degradation of glypican-1 heparan sulfate In vivo.